Evidence map›Paper›PMID 25688860›Full record

ArticlePloS one2015

Platelet surface-associated activation and secretion-mediated inhibition of coagulation factor XII.

Natalia V Zakharova, Elena O Artemenko, Nadezhda A Podoplelova, Anastasia N Sveshnikova, Irina A Demina, Fazly I Ataullakhanov, Mikhail A Panteleev

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Model-dependent contributions of FXII and FXI to venous thrombosis in mice.Journal of thrombosis and haemostasis : JTH · 2020
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Natalia V ZakharovaNational Research Center for Hematology, Moscow, Russia; Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Elena O ArtemenkoCenter for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Nadezhda A PodoplelovaNational Research Center for Hematology, Moscow, Russia; Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Anastasia N SveshnikovaCenter for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; Faculty of Physics, M.V. Lomonosov Moscow State University, Moscow, Russia.
Irina A DeminaFederal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Fazly I AtaullakhanovNational Research Center for Hematology, Moscow, Russia; Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; Faculty of Physics, M.V. Lomonosov Moscow State University, Moscow, Russia; Faculty of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
Mikhail A PanteleevNational Research Center for Hematology, Moscow, Russia; Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia; Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; Faculty of Physics, M.V. Lomonosov Moscow State University, Moscow, Russia; Faculty of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
Center for Theoretical Problems of Physicochemical Pharmacology · RUFederal State Institution Hematology Research Center · RULomonosov Moscow State University · RUMoscow Institute of Physics and Technology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coagulation factor XII (fXII) is important for arterial thrombosis, but its physiological activation mechanisms are unclear. In this study, we elucidated the role of platelets and platelet-derived material in fXII activation. FXII activation was only observed upon potent platelet stimulation (with thrombin, collagen-related peptide, or calcium ionophore, but not ADP) accompanied by phosphatidylserine exposure and was localised to the platelet surface. Platelets from three patients with grey platelet syndrome did not activate fXII, which suggests that platelet-associated fXII-activating material might be released from α-granules. FXII was preferentially bound by phosphotidylserine-positive platelets and annexin V abrogated platelet-dependent fXII activation; however, artificial phosphotidylserine/phosphatidylcholine microvesicles did not support fXII activation under the conditions herein. Confocal microscopy using DAPI as a poly-phosphate marker did not reveal poly-phosphates associated with an activated platelet surface. Experimental data for fXII activation indicates an auto-inhibition mechanism (ki/ka = 180 molecules/platelet). Unlike surface-associated fXII activation, platelet secretion inhibited activated fXII (fXIIa), particularly due to a released C1-inhibitor. Platelet surface-associated fXIIa formation triggered contact pathway-dependent clotting in recalcified plasma. Computer modelling suggests that fXIIa inactivation was greatly decreased in thrombi under high blood flow due to inhibitor washout. Combined, the surface-associated fXII activation and its inhibition in solution herein may be regarded as a flow-sensitive regulator that can shift the balance between surface-associated clotting and plasma-dependent inhibition, which may explain the role of fXII at high shear and why fXII is important for thrombosis but negligible in haemostasis.

Indexed as

AdultAgedAged, 80 and overBlood CoagulationBlood Coagulation Factor InhibitorsBlood PlateletsCell-Derived MicroparticlesCell MembraneComplement C1 Inactivator ProteinsEnzyme ActivationFactor XIIFamilyFemaleGray Platelet SyndromeHumansMaleBlood Coagulation Factor InhibitorsComplement C1 Inactivator ProteinsFactor XII

Identifiers

PMID25688860
PMCPMC4331558
OpenAlexW2070786629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.